Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
Where Will Recursion Pharmaceuticals Be in 3 Years?
09:35am, Monday, 11'th Sep 2023
Recursion Pharmaceuticals has three different business segments that could grow. Its drug development pipeline will take the longest to yield sales.
Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data
12:38pm, Friday, 08'th Sep 2023
Amid fierce debate about prescription-drug prices and countless proposals to rein them in, there has been a point of widespread agreement: Those prices at least partly reflect the vast amount of time,
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
06:35pm, Tuesday, 05'th Sep 2023
In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challenging,
Recursion to Participate in Upcoming Investor Conferences
04:30pm, Tuesday, 05'th Sep 2023
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participatio
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
09:37am, Wednesday, 30'th Aug 2023
Ark Invest has continued to trim its holdings in Nvidia although it's still a large holder. Meanwhile, the investment firm has been increasing its bets in the biotech sector.
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
05:10am, Friday, 25'th Aug 2023
AI for drug development is very fashionable in biotech, and for good reason. 23andMe's consumer business could one day provide a bedrock of stability.
Recursion Pharmaceuticals stock gets boost after Nvidia results
08:38am, Thursday, 24'th Aug 2023
Shares of Recursion Pharmaceuticals Inc. RXRX, +3.30% jumped more than 4% premarket on Thursday after chip giant Nvidia Corp. NVDA, +3.17% on Wednesday posted blowout quarterly results. Recursion last
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
07:43pm, Monday, 21'st Aug 2023
Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care.
3 Green Flags for Biotech Stocks in 2023 and Beyond
09:45am, Saturday, 19'th Aug 2023
Biotech will benefit immensely from new artificial intelligence tools. Companies are also starting to create some enormously complex new therapies.
3 Things About Recursion Pharmaceuticals That Smart Investors Know
09:53am, Friday, 11'th Aug 2023
Recursion's pipeline is chasing a handful of relatively small opportunities. Its collaboration with Nvidia will take some time to pay off, assuming it does.
'We look like what the future of all biopharma companies will look like', says Recursion CEO Gibson
07:05pm, Tuesday, 08'th Aug 2023
Chris Gibson, Recursion CEO, joins 'Closing Bell Overtime' to talk drug development, quarterly earnings, tech integration in pharmaceuticals and more.
3 AI Stocks You'll Regret Not Buying Soon
03:06pm, Tuesday, 08'th Aug 2023
Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI sto
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
11:25am, Tuesday, 08'th Aug 2023
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.38 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per share a year ago.
Recursion to Participate in Upcoming Investor Conference
08:30am, Tuesday, 01'st Aug 2023
SALT LAKE CITY, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation
3 Cutting-Edge Biotech Stocks That Are Riding the AI Wave Like None Other
10:07am, Friday, 21'st Jul 2023
Recursion Pharmaceuticals just got Nvidia on board with its vision of AI for R&D. Ginkgo Bioworks is pairing AI with laboratory robotics to streamline R&D, too.
